Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-armed Open-labeled Phase II Study of HX008 (a Humanized Monoclonal Antibody Targeting PD-1) for the Treatment of Patients With Locally Advanced or Metastatic Melanoma Who Have Failed the Standard Treatments.

Next Previous
X
Search
Trial Profile

A Single-armed Open-labeled Phase II Study of HX008 (a Humanized Monoclonal Antibody Targeting PD-1) for the Treatment of Patients With Locally Advanced or Metastatic Melanoma Who Have Failed the Standard Treatments.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pucotenlimab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Taizhou Hanzhong Pharmaceuticals

    • Most Recent Events

    • 06 Feb 2023 Results assessing Safety and efficacy of Pucotenlimab (HX008) in patients with locally advanced or metastatic melanoma published in the BMC Cancer
    • 30 Sep 2022 Status changed from active, no longer recruiting to completed, according to a Lepu Biopharma media release.
    • 30 Sep 2022 According to Lepu Biopharma media release, the National Medical Products Administration (NMPA) has approved pucotenlimab injection (HX008) in patients with locally progressed or metastatic melanoma after the failure of standard therapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top